Search clinical trials for: High Risk Relapse

Total 37197 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
Sellas Life Sciences Group

Unknown

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma | Minimal Residual Disease | High-Risk Cancer

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
Cairo University

Unknown

Effectiveness of Different Preventive Regimens in Cariogram Parameters and DMF Scores of High Caries Risk Patients: A Randomized Control Trial

Prevention of Dental Caries

Egypt
Abramson Cancer Center of the University of Pennsylvania

Completed

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias (UPCC 02407)

Leukemia | AML | CML | Myeloid Leukemias

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Terminated

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Io Therapeutics

Terminated

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Brown University
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island; Women... and other collaborators

Terminated

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

Breast Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia

United States
Yonsei University

Withdrawn

Safety and Immunogenicity Study of GX-70 in TB Patient

Pulmonary Tuberculoses | Treatment Failure | High Risk Factors for Relapse
Chinese PLA General Hospital

Unknown

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

Peripheral Blood Stem Cell Transplantation | Relapse | Donor Lymphocyte Infusion | Graft-versus-host Disease | Decitabine

China
Inovio Pharmaceuticals
Mayo Clinic; University of Pennsylvania; University of Pittsburgh; Thomas Jefferson... and other collaborators

Completed

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (TRT-001)

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | ColoRectal Cancer | HepatoCellular Carcinoma

United States
Azienda Ospedaliera San Giovanni Battista
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte; Rete...

Unknown

Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients (TOTEM)

Endometrial Cancer

Italy
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Lymphoma | Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genzyme, a Sanofi Company

Terminated

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (POE07-01)

Acute Myeloid Leukemia | Myeloproliferative Disorders | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Promyelocytic Leukemia | Chronic Myelogenous Leukemia

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Coronado Biosciences, Inc.

Unknown

CNDO-109-AANK for AML in First Complete Remission (CR1)

Acute Myeloid Leukemia

United States
University of Louisville
Solving Kids' Cancer

Completed

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | Ewings Sarcoma

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Withdrawn

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Leukemia
University of Chicago

Completed

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Anemia, Aplastic | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Disorder | Hodgkin's Disease | Lymphoid Leukemia | Malignant Lymphoma

United States
Beth Israel Deaconess Medical Center
Bayer

Completed

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | AML | Myelodysplastic Syndrome | Aplastic Anemia | Myeloproliferative Disorder | CLL | ALL

United States
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Multiple Myeloma | Plasma Cell Leukemia

United States
Hoffmann-La Roche

Terminated

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

United States, Canada, Germany
National Cancer Institute (NCI)

Completed

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
Peking Union Medical College
Beijing Hope Run

Unknown

Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients

Carcinoma, Hepatocellular

China
Nationwide Children's Hospital

Withdrawn

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Neuroblastoma

United States
Mirati Therapeutics Inc.

Terminated

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Myelodysplastic Syndromes | Myelogenous Leukemia, Acute

United States, Canada
University Health Network, Toronto

Terminated

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Myelodysplasia

Canada
University Health Network, Toronto
The Leukemia and Lymphoma Society

Completed

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myelodysplasia | Hodgkin's Disease

Canada
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Ginna Laport

Terminated

Haploid Allogeneic Transplant Using the CliniMACS System

Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors | Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase | Myelodysplastic Syndrome (MDS) - High and Intermediate Risk | Non-Hodgkin's Lymphoma (NHL) | Chronic Lymphocytic Leukemia...

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Children's Cancer and Leukaemia Group

Completed

Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma

Neuroblastoma

United Kingdom, Ireland, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer; The Leukemia and Lymphoma Society

Terminated

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Refractory Acute Leukemia | Relapsed Acute Leukemia | High-Risk Myelodysplasia

United States
Baylor Research Institute

Completed

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Children's Cancer and Leukaemia Group

Withdrawn

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Neuroblastoma
Asan Medical Center

Completed

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Cancer

Korea, Republic of
The First Affiliated Hospital of Soochow University

Unknown

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation (DFMBHSCT)

Higher-risk Myelodysplastic Syndrome | Relapsed /Refractory Acute Myeloid Leukemia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Prostate Cancer

United States

Search clinical trials for: High Risk Relapse

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations